Tuesday, May 15 at 9pm EDT #AskASN returns for a discussion of belatacept with transplant experts Matthew Ellis, MD from Duke and Silvi Shah from Cincinnati.
Here is a visual abstract by Aakash Shingada on the BENEFIT trials to wet your appetite.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
Tuesday, May 15 at 9pm EDT #AskASN returns for a discussion of belatacept with transplant experts Matthew Ellis, MD from Duke and Silvi Shah from Cincinnati.
Here is a visual abstract by Aakash Shingada on the BENEFIT trials to wet your appetite.
To most Nephrologists, Nephronophthisis (NPH) is considered to be a rare autosomal recessive paediatric disease. However, this article by Snoek et al challenges that belief, by examining the prevalence of mutations that cause NPH, in adults with end stage renal disease (ESRD). Read our NephJC summary below and come along to our Twitter Journal Club discussion to find out whether you might consider a diagnosis of NPH, next time you see that patient carrying a label of ‘ESRD, cause unknown’.